Abstract:Abstract Background Janus kinase inhibitors (JAKinibs) have the potential to dramatically alter the landscape of atopic dermatitis (AD) management due to their promising efficacy results from phase 3 trials and rapid onset of action. However, JAKinibs are not without risk, and their use is not appropriate for all AD patients, making this a medication class that dermatologists should understand and consider when treating patients with moderate-to-severe AD. Objective This consensus expert opinion statement from the International Eczema Council (IEC) provides a pragmatic approach to prescribing JAKinibs, including choosing appropriate patients, dosing, clinical and lab monitoring, as well as long-term use. Methods An international cohort of authors from the IEC with expertise in JAKinibs selected topics of interest and were formed into authorship groups covering 10 subsections. The groups performed topic-specific literature reviews, consulted up-to-date adverse event (AE) data, referred to product labels and provided analysis and expert opinion. The manuscript guidance and recommendations were reviewed by all authors as well as the IEC Research Committee. Results We recommend JAKinibs be considered for patients with moderate to severe AD seeking the benefits of rapid reduction in disease burden and itch, oral administration, and the potential for flexible dosing. Baseline risk factors should be assessed prior to prescribing JAKinibs, including increasing age, venous thromboembolisms, malignancy, cardiovascular health, kidney/liver function, pregnancy and lactation, and immunocompetence. Patients being considered for JAKinib therapy should be current on vaccinations and we provide a generalized framework for laboratory monitoring, though clinicians should consult individual product labels for recommendations as there are variations among the JAKinib class. Patients who achieve disease control should be maintained on the lowest possible dose, as many of the observed AEs occurred in a dose-dependent manner. Future studies are needed in AD patients to assess the durability and safety of continuous long-term use of JAKinibs, combination medication regimens, and the effects of flexible, episodic treatment over time. Conclusions The decision to initiate a JAKinib should be shared among patient and provider, accounting for AD severity and personal risk/benefit assessment, including consideration of baseline health risk factors, monitoring requirements and treatment costs.

The JAK-STAT Pathway and the JAK Inhibitors

Janus Kinase and Tyrosine Kinase Inhibitors in Dermatology: A Review of Their Utilization, Safety Profile and Future Applications

[Janus kinase inhibitors for skin disorders]

JAK‐inhibitors in dermatology – small molecules, big impact? Overview of the mechanism of action, previous study results and potential adverse effects

JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects

JAK inhibitors in dermatology: the road travelled and path ahead, a narrative review

JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis

JAK3 as an Emerging Target for Topical Treatment of Inflammatory Skin Diseases

Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 Pathway

JAK–STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review

Prospects of Janus Kinase Inhibitors in the Treatment of Skin Diseases

Working and safety profiles of JAK/STAT signaling inhibitors. Are these small molecules also smart?

Janus-kinase inhibitors in dermatology: A review of their use in psoriasis, vitiligo, systemic lupus erythematosus, hidradenitis suppurativa, dermatomyositis, lichen planus, lichen planopilaris, sarcoidosis and graft-versus-host disease

JAK inhibitors (JAKi): Mechanisms of action and perspectives in systemic and autoimmune diseases

Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent

JAK-STAT signaling in inflammation and stress-related diseases: implications for therapeutic interventions

JAK Inhibitors: Prospects in Connective Tissue Diseases

A Comprehensive Overview of Globally Approved JAK Inhibitors

A Practical Guide to Using Oral JAK Inhibitors for Atopic Dermatitis from the International Eczema Council

JAK‐Inhibitoren in der Dermatologie – kleine Moleküle, große Wirkung? Übersicht über Wirkmechanismus, Studienergebnisse und mögliche unerwünschte Wirkungen

JAK in the [Black] Box: A Dermatology Perspective on Systemic JAK Inhibitor Safety